Leyden Labs
Leiden, Zuid-Holland, Netherlands · Biotechnology, research · 90 employees
Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza an
Funding history
- Funding Round — $40.0M — Jun 2026
- Funding Round — $30.0M — Oct 2025
- Venture - Series Unknown — $20.0M — Jun 2025
- Funding Round — $70.0M — Jan 2025
- Funding Round — $200.0M — Jan 2022
Recent signals
- Jun 25, 2026: Raised $40.0M in Funding Round
- Oct 02, 2025: Raised $30.0M in Funding Round
- Jun 04, 2025: Raised $20.0M in Venture - Series Unknown
- Jan 12, 2025: Leyden Labs Secures $70 Million Funding and Acquires CoV Biotechnology for Advancing Intranasal Antibody Programs
- Jan 09, 2025: Raised $70.0M in Funding Round
- Sep 12, 2024: Leyden Laboratories Appoints Dr. Jintanat Ananworanich as Chief Medical Officer
- Jan 25, 2022: Raised $200.0M in Funding Round
See plans & pricing → Track Leyden Labs’s funding, hiring, and signals — with verified contacts — on Fundz.